Dupilumab: A Review in Moderate to Severe Asthma
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01221-x
Abstract: Dupilumab (Dupixent®) is a fully human monoclonal antibody against the interleukin (IL)-4 receptor α subunit of IL-4 and IL-4/IL-13 receptor complexes. IL-4 and IL-13 are key cytokines in driving type 2 inflammation, a dominant and… read more here.
Keywords: dupilumab review; severe asthma; asthma; review moderate ... See more keywords